Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New advances in antirejection therapy.

Michael Chan1, Glen J Pearson

  • 1Heart Transplant Program, University of Alberta Hospitals, Edmonton, Alberta, Canada. mcchan@cha.ab.ca

Current Opinion in Cardiology
|February 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strengthening Special Care Dentistry Education in U.S. to Meet the Needs of an Expanding Population.

Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·2026
Same author

Erratum: Author Correction to "Vaccination in Patients With Cardiovascular Disease: A Case-based Approach and Contemporary Review [Canadian Journal of Cardiology Open. Volume 7, Issue 10 (2025), 1375-1388]".

CJC open·2026
Same author

TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.

Vaccine·2026
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same author

iS2C2: a cointelligent platform for mechanistic discovery of disease cellular crosstalk.

Signal transduction and targeted therapy·2026
Same author

Characterization of atypical Ebola virus disease in ferrets.

PLoS pathogens·2026

Advancements in antirejection therapies have improved survival after heart transplantation. However, ongoing research is crucial to address persistent challenges with rejection and drug side effects in heart transplant recipients.

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation Medicine

Background:

  • Heart transplantation outcomes have historically been limited by allograft rejection.
  • Significant improvements in patient survival are attributed to advancements in antirejection therapies.

Purpose of the Study:

  • To review the evolution and current status of antirejection therapies in heart transplantation.
  • To highlight recent findings and ongoing research in managing cardiac allograft rejection.

Main Methods:

  • Review of established and emerging antirejection drug classes.
  • Analysis of treatment strategies and their impact on patient survival.
  • Consideration of new grading systems for cardiac allograft rejection.

Main Results:

Related Experiment Videos

  • Traditional triple therapy (steroids/cyclosporine/azathioprine) has been supplanted by newer agents like mycophenolate mofetil and tacrolimus.
  • Novel therapies including target of rapamycin inhibitors and anti-interleukin-2 agents are under investigation.
  • Controversy persists regarding optimal treatment timing and agent selection for cardiac allograft rejection.

Conclusions:

  • Modern antirejection drugs have enhanced survival rates post-heart transplant.
  • Rejection and drug-induced side effects remain significant clinical hurdles.
  • Continued research is essential to further optimize immunosuppression and improve long-term outcomes in heart transplantation.